NTII's setback

Neurobiological Technologies Inc. on Friday said it will discontinue internal development of corticotropin-releasing factor (CRF) in rheumatoid arthritis following disappointing results of a short Phase II study.

Absent a partner in RA, the company said it would focus its resources on other indications for CRF, as well as its other compounds in clinical development.

NTII shares were off

Read the full 566 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers